Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes

Ryan P. Staudt1, John J. Alvarado1, Lori A. Emet-Sedlak1, Haibin Shi1, Sherry T. Shu1, Thomas E. Wales2, John R. Engen2,*, and Thomas E. Smithgall1,†*

From the 1Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA and the 2Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts, USA

Edited by Karin Musier-Forsyth

Antiretroviral therapy has revolutionized the treatment of AIDS, turning a deadly disease into a manageable chronic condition. Life-long treatment is required because existing drugs do not eradicate HIV-infected cells. The emergence of drug-resistant viral strains and uncertain vaccine prospects highlight the pressing need for new therapeutic approaches with the potential to clear the virus. The HIV-1 accessory protein Nef is essential for viral pathogenesis, making it a promising target for antiretroviral drug discovery. Nef enhances viral replication and promotes immune escape of HIV-infected cells but lacks intrinsic enzymatic activity. Instead, Nef works through diverse interactions with host cell proteins primarily related to kinase signaling pathways and endosomal trafficking. This review emphasizes the structure, function, and biological relevance of Nef interactions with host cell protein-tyrosine kinases in the broader context of Nef functions related to enhancement of the viral life cycle and immune escape. Drug discovery targeting Nef-mediated kinase activation has allowed identification of promising inhibitors of multiple Nef functions. Pharmacological inhibitors of Nef-induced MHC-I down-regulation restore the adaptive immune response to HIV-infected cells in vitro and have the potential to enhance immune recognition of latent viral reservoirs as part of a strategy for HIV clearance.

Antiretroviral drug therapy for HIV/AIDS and barriers to cure

The specter of the HIV pandemic first appeared in the United States Centers for Disease Control Morbidity and Mortality Weekly Report on June 5, 1981. A brief in that report recounted the appearance of Pneumocystis carinii pneumonia cases in the Los Angeles area, a diagnosis typically associated with severely immunocompromised patient populations but unexpected in young men (1). This report unknowingly provided the first description of what would become HIV/AIDS in the medical literature. Today, the AIDS pandemic persists as a global public health crisis, with 38 million people currently living with HIV worldwide. More than 1.7 million new infections and nearly 700,000 HIV-related deaths occurred in 2019, mainly in southern and eastern Africa. Over 30 million people have died from AIDS and related illnesses since the start of the pandemic (UNAIDS 2020 Fact Sheet).

Thefirst antiretroviral drug developed for HIV-1 was the nucleoside reverse transcriptase inhibitor (NRTI), zidovudine, which was approved by the United States Food and Drug Administration in 1987 (2). Subsequent development of additional NRTIs facilitated combination therapy that markedly delayed AIDS progression compared with zidovudine alone (3). However, AIDS-related fatalities continued to climb until non-nucleoside reverse transcriptase inhibitors and protease inhibitors were approved for clinical use (4, 5). Introduction of these new classes of inhibitors enabled a triple-drug regimen that resulted in dramatic suppression of viral loads and restored CD4+ T cell counts with a lower incidence of viral resistance. Combination antiretroviral therapy (cART) has continued to improve over the last 25 years, with more than 30 antiretroviral drugs now available across six classes of inhibitor types, including integrase inhibitors, viral fusion inhibitors, and coreceptor antagonists (6). Whereas cART has been extraordinarily successful for long-term management of HIV-1 infection, no existing drugs clear latent viral reservoirs. Thus, life-long drug administration is required.

Because HIV-1 is an integrating lentivirus, identification of curative strategies for HIV-1 infection has proven to be an even more difficult challenge than developing drugs to control infection. Clinical trials of HIV-1 vaccine candidates have been largely unsuccessful, with just one vaccine producing partial efficacy to date (7). In addition to vaccines, substantial research effort has addressed therapeutic cures for HIV-1 infection. One well-known cure strategy is based on the concept of “shock and kill,” in which latency reversal agents (LRAs) are used to reactivate the integrated provirus in latent reservoirs in the presence of antiretroviral drugs. Induction of viral protein expression may then promote immune recognition and clearance of latently infected cells (8). Recent examples of LRAs that induce latency reversal in animal models in the presence of antiretroviral drugs include engineered agonists for the interleukin-15 receptor (9) and a small molecule activator of the noncanonical NF-kB pathway (10), although neither treatment alone resulted in clearance of viral reservoirs.

The observations that LRAs can induce viral gene expression in the presence of antiretroviral drugs, but fail to prevent viral rebound following antiretroviral drug withdrawal, indicate that
Nef alters membrane protein trafficking to facilitate HIV-1 infectivity and immune escape

Nef is remarkably well-adapted to hijack the intracellular trafficking machinery to modulate cell-surface protein expression. Two well-characterized Nef functions in this regard are down-regulation of CD4 and major histocompatibility complex I (MHC-I) proteins, which are orchestrated by Nef via the endocytic adaptor protein complexes, AP-1 and AP-2. Nef also drives down-regulation of the SERINC family of host cell restriction factors via AP-2 to enhance viral infectivity. Structural features and other aspects of these interactions are covered in several recent reviews (25, 26) and are not discussed in detail here.

CD4 down-regulation

Down-regulation of CD4 by Nef is conserved across virtually all HIV-1 subtypes (27). Whereas this function may seem counterintuitive at first, given the essential role of CD4 in viral entry, it is in full alignment with the role of Nef in cell survival and immune escape. Persistence of CD4 on the surface of infected cells may lead to cytotoxic superinfection, whereas interaction between CD4 and Env has been shown to trigger antibody-dependent cell-mediated cytotoxicity (28, 29). CD4 down-regulation is normally regulated through phosphorylation-dependent engagement of the cytosolic tail of CD4 by AP-2, which initiates clathrin-mediated endocytosis of CD4 into the endolysosomal pathway (30). Nef accelerates this endocytic process by engaging both the cytosolic tail of CD4 and the α and α2 subunits of AP-2 (31–33). Notably, CD4 down-regulation is also triggered by the HIV-1 accessory protein Vpu. However, Vpu is expressed later in the viral life cycle and targets CD4 through a distinct ubiquitination-dependent process (34).

HIV-1 infectivity

Early work demonstrated that disruption of Nef expression impairs HIV-1 infectivity (35), implying a positive contribution of Nef to the infectivity of viral particles. Subsequent work established that infectivity enhancement requires Nef myristoylation, AP-2 association, and clathrin-mediated endocytosis (36, 37). Despite these advances, one key mechanism behind Nef infectivity enhancement remained elusive until 2015, when a novel host cell restriction factor known as SERINC5 was identified (38, 39). SERINC5 is a multipass transmembrane protein present on the surface of HIV-1 producer cells that is with a large flexible internal loop (~25 residues). Because the anchor region is flexible, the folded core can move off the membrane (22, 23) to accommodate interactions with diverse host cell proteins, many of which are also associated with the membrane (Fig. 1). Nef does not exhibit any known enzymatic or biochemical activities, functioning instead through a diverse array of protein-protein interactions (24). Examples of the best-characterized Nef functions and attendant binding partners are summarized below. These include endocytic trafficking molecules followed by protein kinases, which are the primary focus of this review.
incorporated into the membrane of newly synthesized virions (38–40). SERINC5 disrupts viral fusion with host cells and delivery of the viral core through an Env-dependent mechanism (40). Nef counters the SERINC5 host defense mechanism by down-regulating it from the cell membrane through an AP-2–dependent pathway, thereby preventing incorporation into budding virions (39). Following down-regulation by Nef, internalized SERINC5 is targeted for degradation via the endosomal pathway (41).

**MHC-I down-regulation**

Antigen presentation by MHC-I is another critical target for Nef-mediated down-regulation. Antigenic peptides derived from proteolytically digested viral proteins are loaded onto MHC-I molecules within the endoplasmic reticulum and presented on the surface of infected cells, triggering recognition and killing of the infected cell by CD8 cytotoxic T cells. In contrast to CD4 down-regulation, Nef-mediated MHC-I down-regulation occurs via AP-1.

Two temporally distinct models of Nef-mediated antagonism of MHC-I have been reported. In the first model, also known as the “signaling mode,” Nef is recruited by the phosphofurin acidic cluster 2 (PACS-2) adaptor protein to the trans-Golgi network (TGN), where it drives the activation of Src-family kinases specific to the host cell lineage (Hck in macrophages; Lyn in T cells). Src-family kinase activity initiates a signaling cascade that ultimately increases levels of membrane phosphatidylinositol (3,4,5)-trisphosphate via phosphoinositide 3-kinase, causing activation of the small GTPases Arf1 and Arf6 and endocytosis of cell-surface MHC-I (42, 43). Internalized MHC-I is trapped in vesicles in complex with Nef and AP-1 and prevented from recycling back to the plasma membrane. In the second model, known as the “stoichiometric mode,” Nef associates with AP-1 and Arf1 to trap newly synthesized MHC-I molecules within the TGN, thereby preventing anterograde trafficking toward the plasma membrane (44). A temporal sequence for these two mechanisms has been proposed (42), with the signaling mode occurring earlier in the infection cycle. Both models require the association of Nef with AP-1 and the cytoplasmic tail of MHC-I, for which a crystal structure has been reported (45). Additional details of the endosomal trafficking pathways controlling MHC-I down-regulation by Nef are described in several other reviews (26, 46).

**Nef and Src-family kinases**

Recruitment and activation of Src-family kinases by Nef has been the focus of many structural, cellular, and in vitro studies. Early work demonstrated that of the eight mammalian Src-family members, Nef preferentially binds to Hck and Lyn via their SH3 domains (47, 48). Nef binding displaces the SH3 domain from its regulatory position on the back of the Hck kinase domain, resulting in constitutive kinase activation both in vitro and in cell-based systems (49–51). Nef-dependent Hck activation is a conserved function of all HIV-1 Nef M-group subtypes (52). Expression of a dominant-negative Hck mutant as well as knockdown of Hck expression both compromise HIV-1 transcription and viral replication in macrophages, a dominant site of Hck expression (53, 54). Compared with Hck, Lyn, and to some extent Src, interaction of other Src-family members with Nef is less definitive. One example is Lck, a critical component of the T cell receptor activation pathway (55). Whereas expression of Nef in T cell lines results in intracellular relocalization of Lck, it is less clear whether Nef binds directly to Lck within cells (56). When Nef and Lck are ectopically expressed in defined cellular systems, no change in Lck activity is observed, suggesting that interaction in T cell systems may be indirect (57–59).

**A conserved PxxPxr motif is essential for SH3 domain binding and Src-family kinase activation by Nef**

HIV-1 Nef contains a highly conserved PxxPxr motif, which forms a polyproline type II (PPII) helix that serves as the docking site for recruitment of Src-family kinases and other proteins with SH3 domains (60). This motif is required for activation of Hck and other Src-family members, as mutation of the core prolines in the PPII helix prevents Nef interaction and kinase activation (49, 50). Disruption of the PxxPxr motif also impacts Nef down-regulation of MHC-I (61) as well as enhancement of viral replication and pathogenicity in murine and primate models of AIDS (62, 63). However, down-regulation of CD4 by Nef is not affected by mutation of the PxxPxr motif (61), arguing against a role for Src-family kinase signaling or other SH3-binding proteins in this Nef function.

**Structural basis of Src-family kinase activation by Nef**

The first X-ray crystal structure of Nef (all structures described in this review are listed in Table 1) was reported in complex with the SH3 domain from the Src-family kinase, Fyn (64). The overall structure forms a 2:2 dimer of Nef SH3 complexes, with Nef forming the dimer interface (Fig. 2A). This structure revealed that the PPII helix formed by the Nef PxxPxr motif engages hydrophobic grooves on the SH3 domain surface, with the arginine of the motif making an electrostatic contact with an aspartate residue in the SH3 domain RT loop (Fig. 2B).

Nef displays at least 10-fold higher affinity for the Hck SH3 domain relative to the Fyn SH3, a difference attributable to a single residue within the RT loop of the SH3 domain (48). The Hck SH3 domain has an isoleucine residue at position 96 within the RT loop, which engages a hydrophobic pocket in the folded core of Nef (70). The Fyn SH3 domain has an arginine at position 96, which is suboptimal for interaction with this Nef pocket, as revealed in a subsequent crystal structure (65) (PDB code 1AVZ). Replacement of Arg-96 in the Fyn SH3 domain with isoleucine restores higher affinity Nef binding, illustrating the importance of this residue (48). In fact, this modified Fyn SH3 domain (R96I) was used for the original crystal structure with Nef (PDB code 1EFN) to promote interaction with the hydrophobic pocket (Fig. 2C). Among the eight Src-family members, only Hck and Lyn have isoleucine at this SH3 position 96.

3 HIV-1 Nef amino acid numbering is based on the crystal structure of the Nef core in complex with the R96I mutant of the Fyn SH3 domain (PDB code 1EFN). Amino acid numbering for Hck and other Src-family kinases is based on the crystal structure of Src (PDB code 2SRC).
position, thus explaining their unique sensitivity to activation following Nef engagement (59).

Other structures of SH3-bound HIV-1 Nef have used an artificially engineered SH3 domain in which the RT loop sequence was altered to enhance Nef binding. Replacement with five alternative RT loop residues increased Hck SH3 affinity for Nef by nearly 40-fold (71, 72). This optimized SH3 domain was subsequently combined with a single-chain anti-Nef antibody to create protein-based inhibitors of multiple Nef functions (73, 74). Introduction of the optimized RT loop sequence into full-length Hck protein has been reported (79) and shows that it encompasses the C-terminal end of the SH2-kinase linker where it joins the N-lobe of the kinase domain. No changes in hydrogen exchange occurred in the SH2 domain or C-terminal tail, indicating that this regulatory interaction remains intact in the active Hck-Nef complex. This result indicates that Nef binding induces subtle perturbations in the conformation of Hck to induce its activation and is consistent with other work showing that short peptides or small molecules that disrupt the SH3-linker interface also stimulate Hck activity in vitro (81, 82).

In addition to Src-family kinase activation, the Nef PxxPxR motif also makes a structural contribution to MHC-I down-regulation. Selective activation of Hck in macrophages or Lyn in T cells is an essential step for the signaling mode of MHC-I down-regulation by Nef described above. In addition, an X-ray crystal structure of Nef in complex with the cytoplasmic tail of MHC-I and the AP-2 6URI X-ray 33/2 4NEE X-ray 69/1 4EN2 X-ray 45 of Nef). Wales et al. (78) performed this comparison using recombinant near-full-length Hck (SH3-SH2-kinase-tail) and full-length Nef. The crystal structure of the identical near-full-length Hck protein has been reported (79) and shows that it adopts an assembled, inactive conformation driven by two primary intramolecular interactions: the SH3 domain binds to the SH2-kinase linker (which adopts a PPII helical conformation), whereas the SH2 domain engages the tyrosine-phosphorylated tail. Disruption of either interaction by mutagenesis leads to activation of Hck in cells (80), raising the question of whether Nef selectively disrupts SH3-mediated regulation of Hck or causes a more global disruption of the down-regulated state. Comparison HX MS experiments (78) of Hck alone (where the SH2-kinase linker is bound to the SH3 domain as in down-regulated Hck) versus Hck in complex with Nef (where the Nef PxxPxR motif is bound to the SH3 domain as required for Hck activation) demonstrated remarkably few changes to the rest of Hck upon Nef interaction. Very subtle changes in deuteration uptake by Hck were found in only a single peptic peptide that encompasses the C-terminal end of the SH2-kinase linker where it joins the N-lobe of the kinase domain. No changes in hydrogen exchange occurred in the SH2 domain or C-terminal tail, indicating that this regulatory interaction remains intact in the active Hck-Nef complex. This result indicates that Nef binding induces subtle perturbations in the conformation of Hck to induce its activation and is consistent with other work showing that short peptides or small molecules that disrupt the SH3-linker interface also stimulate Hck activity in vitro (81, 82).

In addition to Src-family kinase activation, the Nef PxxPxR motif also makes a structural contribution to MHC-I down-regulation. Selective activation of Hck in macrophages or Lyn in T cells is an essential step for the signaling mode of MHC-I down-regulation by Nef described above. In addition, an X-ray crystal structure of Nef in complex with the cytoplasmic tail of MHC-I and the AP-1 subunit of AP-1 illuminates an SH3-independent role for the Nef PxxPxR motif (PDB code 4EN2) (45). In this complex, the Nef PxxPxR motif interacts directly with AP-1 μ1, helping to clamp the MHC-I tail into a binding groove within the heterocomplex. Thus, the Nef PxxPxR motif may provide a mechanism not only for Src-family kinase engagement and activation necessary for MHC-I down-regulation, but also for direct interaction with AP-1.

### Table 1

| Protein or complex | PDB code | Method | Reference |
|--------------------|----------|--------|-----------|
| Nef anchor region  | 1QA4, 1QA5 | NMR | 20 |
| Nef Fyn SH3 (R61) | 1EFN | X-ray | 64 |
| Nef Fyn SH3 | 1AVZ | X-ray | 65 |
| Nef | 2NEF | NMR | 66 |
| Nef Hck SH3-SH2 | 4U5W | X-ray | 67 |
| Hck, near-full-length | 1QCF | X-ray | 68 |
| Nef MHC-1-AP-1 μ1 | 4EN2 | X-ray | 45 |
| Nef AP-2 a/α2 | 4NEE | X-ray | 69 |
| Nef CD4-AP-2 | 6URI | X-ray | 33 |

### Nef and Tec-family kinases

A growing body of evidence has linked HIV-1 infection and Nef to activation of select members of the Tec kinase family that are expressed in HIV host cells. Tec-family kinases play essential roles in antigen receptor signaling in both T and B cells, as well as in lymphocyte development (83, 84). Readinger et al. (85) first reported a connection between the HIV-1 life cycle and Itk, a Tec-family member expressed in CD4 T cells that is essential for T cell receptor signaling. Using Itk-directed siRNA knockdown, a dominant-negative Itk mutant, and
pharmacological Itk inhibitors, they demonstrated that loss of Itk activity reduced p24 capsid levels and virus spread in cell culture. Itk activity was also required for efficient transcription from the integrated provirus, an effect that was enhanced by overexpression of Itk. Whereas this study clearly demonstrated a role for Itk activity in the viral life cycle, it did not address how HIV-1 infection influenced Itk activity.

Subsequent work established that HIV-1 Nef selectively interacts with Tec-family kinases and that Nef-mediated kinase activation is essential for viral replication (86). Nef interaction with Tec-family members was explored using a cell-based bimolecular fluorescence complementation assay (BiFC), a technique widely used to assess protein-protein interactions in cells (87). In this approach, Nef and the presumptive partner kinase are fused to nonfluorescent N- and C-terminal fragments of Venus, ab r i g h t v a r i a n to fY F P(88, 89). When co-expressed in cells, Nef-partner protein interaction juxtaposes the YFP fragments, resulting in complementation of the YFP fluorophore and a bright fluorescent signal that also reports subcellular localization.
Using BiFC, Tarafdar et al. (86) showed that Nef interacts with the Tec-family members Itk, Btk, and Bmx, but not Tec or Txk, with interaction localized almost exclusively to the plasma membrane. Variants of Nef representative of all major HIV-1 subtypes interacted strongly with Itk, supporting the conserved nature of this interaction. BiFC experiments with truncated forms of Itk and Btk, consisting only of the N-terminal PH domain and adjacent SH3 domain, retained interaction with Nef as well, suggestive of an SH3 domain–dependent interaction like Hck. However, unlike Hck, recombinant SH3 domains of Btk and Itk failed to interact with Nef by surface plasmon resonance in vitro, suggesting a more complex mechanism of interaction. A potent Itk inhibitor blocked WT but not Nef-defective HIV-1 infectivity and replication, supporting a role for Nef-dependent Itk activation in the viral life cycle (86).

More recent studies combined BiFC with anti-phosphotyrosine immunofluorescence microscopy to demonstrate that Nef recruits both Itk and Btk to the cell membrane, resulting in sustained kinase autophosphorylation (90). A myristoylation-defective Nef mutant failed to recruit the kinases to the membrane, providing evidence that Nef also induces kinase relocalization. Mutants of Nef defective for homodimer formation failed to induce Itk and Btk activation while retaining kinase interaction by BiFC, suggesting that Nef homodimers may recruit two kinase molecules to promote kinase activation via trans autophosphorylation (Fig. 4A). Importantly, HIV-1 infection increased endogenous Itk activity in T cell lines and donor-derived peripheral blood mononuclear cells (PBMCs), whereas HIV-1 expressing Nef dimerization-defective mutants was significantly attenuated for both Itk activation and viral replication.

Using the same approach, Li et al. (90) also established that SIV Nef (mac239 allele) interacted strongly with Itk and Btk at the plasma membrane and induced constitutive kinase auto-phosphorylation. This observation is significant because SIV Nef does not bind to the SH3 domain of Hck (92), providing further evidence that the mechanism of Tec-family kinase interaction with Nef may involve contacts in addition to the SH3 domain (86). Clarification of the mechanism awaits determination of a high-resolution crystal structure of Nef in complex with a Tec-family member or its regulatory region. Activation of Itk and Btk by Nef at the membrane in HIV-infected cells may circumvent immune receptor control of Tec-family kinase activity to enhance HIV-1 replication. For example, T cell receptor activation normally triggers activation of multiple nonreceptor tyrosine kinases, including Lck and ZAP-70 in addition to Itk (55). The presence of Nef in HIV-infected cells directly activates Itk, short-circuiting this normal control mechanism to promote viral transcription downstream. A model illustrating the possible relationship of Nef-mediated Itk activation to transcriptional activation of the integrated HIV-1 LTR is shown in Fig. 4B.

Figure 4. Nef-mediated activation of Itk requires Nef homodimers. A, Nef recruits Itk to the cytoplasmic face of the plasma membrane and induces 2:2 Nef-Itk complex formation. Regulatory domain displacement and kinase domain juxtaposition induces constitutive kinase activation through trans-autophosphorylation. Dimerization-defective Nef mutants still interact with Itk at the membrane but form inactive 1:1 complexes. 3, Src homology 3 domain; 2, Src homology 2 domain; K, kinase domain; P, activation loop phosphorylation. B, activation of the T-cell receptor complex normally requires antigen-loaded MHC molecules from an antigen-presenting cell. The MHC-bound receptor then activates the Src-family kinase Lck, which is associated with the cytosolic tail of CD4. Lck phosphorylates and activates Itk, which in turn activates phospholipase Cγ (PLCγ) by direct phosphorylation. Phospholipase Cγ generates diacylglycerol (DAG) and inositol triphosphate (IP3), leading to activation of protein kinase C (PKC) and the calcium-dependent protein-serine/threonine phosphatase, calcineurin (CaN). Protein kinase Cα promotes activation of NF-κB via the CARMA1/BCL10/MALT1 complex (not shown), whereas calcineurin dephosphorylates NFAT to drive nuclear localization. The NF-κB and NFAT transcription factors both enhance transcription of the integrated HIV-1 provirus early in the viral life cycle (91). Direct activation of Itk by Nef at the membrane downstream of the TCR may promote viral transcription through this pathway (see "Nef and Tec-family kinases"); LTR, long terminal repeat.

Structural basis and functional relevance of Nef homodimers

Early characterization of recombinant, purified Nef proteins revealed the presence of homodimers and higher-order oligomers in solution (93, 94). NMR spectroscopy demonstrated that Nef dimerization occurred between well-folded monomers, arguing against artifactual interaction of denatured protein
subunits (93). Additional biophysical and biochemical analyses of recombinant Nef confirmed a reversible and concentration-dependent equilibrium between monomeric and dimeric forms of Nef in solution (66, 95), providing the first evidence that Nef has a natural tendency to oligomerize.

Crystal structures of HIV-1 Nef in complexes with Src-family kinase SH3 domains were the first to capture Nef in a dimeric state (64, 65). Within these structures, dimerization is mediated primarily by the αβ helix of each Nef monomer with the dimer interface formed by a cluster of hydrophobic residues including Leu-112, Tyr-115, and Phe-121 (Fig. 5). The hydrophobic interface is flanked by reciprocal electrostatic interactions between Arg-105 and Asp-123, which appear to stabilize the dimer interface in this complex. Thus, the resulting structure is a dimer of Nef SH3 complexes in which Nef is solely responsible for the intercomplex contacts. Nef residues that contribute to homodimer formation are highly conserved across HIV-1 M-group subtypes (52), with many conserved or homologous amino acids in the corresponding positions of Nef from HIV-2 and SIV Nef (95).

Subsequent studies validated the dimer seen in the Nef SH3 crystal structures in terms of residues involved in Nef homodimer formation. Using the BiFC approach described above, Poe et al. (96) demonstrated that Nef forms homodimers in cells that localize to the plasma membrane and the TGN, two subcellular compartments essential for function. Mutagenesis of the hydrophobic core of the Nef dimer interface as well as Asp-123 and Arg-105 all reduced the BiFC signal for interaction, supporting a role for these residues in Nef homodimerization. Each mutation substantially attenuated Nef-dependent receptor down-regulation and viral replication, implying an important functional role for Nef dimers (96). In contrast, mutagenesis of the Nef myristoylation signal or the PxPXXR motif did not affect fluorescence complementation, indicating that membrane localization or SH3 domain engagement are not directly required for Nef dimerization in cells.

A more recent X-ray crystal structure (PDB code 4U5W) of HIV-1 Nef in complex with the complete regulatory region of Hck (tandem SH3-SH2 domains) demonstrates the plasticity of the Nef dimerization interface (67). Whereas the Nef αβ helices still contribute to the dimer interface in the 4U5W structure, the orientation of the two Nef monomers is substantially altered relative to the Nef SH3 complexes seen in 1EFN, and the orientation is stabilized by a much more extensive network of Nef Nef contacts. Three interfaces stabilize the Nef homodimer observed in the crystal complex with the tandem Hck SH3-SH2 domains, which are modeled in Fig. 6. These remarkable changes in the overall homodimer orientation relative to the Nef SH3 complex occur without changes to the overall structure of the Nef core.

Reorientation of the Nef homodimer in the Hck SH3-SH2 complex results in movement of Nef Asp-123, which is buried in the Nef SH3 structures, to a solvent-exposed position. The structure and position of the Nef loop displaying Asp-123 in the Nef SH3-SH2 complex is nearly identical to the one observed in the crystal structure of the Nef-MHC-I-AP-1 complex (PDB code 4EN2), where it coordinates the association of Nef, the cytoplasmic tail of MHC-I, and the μ1 subunit of AP-1 (45, 67, 97). Mutagenesis of Asp-123 prevents Nef-mediated down-regulation of MHC-I, illustrating the functional importance of this residue to immune escape (45, 98). Whereas Nef crystallized as a monomer in the complex with MHC-I and AP-1 μ1, the possibility exists that interaction with Hck may promote the Nef structure required for MHC-I-AP-1 complex assembly as illustrated in Fig. 7. This possibility is consistent with the requirement for Src-family kinases in the early steps of MHC-I down-regulation as described above (42, 43).

Multiple lines of evidence support an essential role for Nef homodimer formation in nonreceptor tyrosine kinase activation. In an early study, Nef was fused to the estrogen receptor hormone-binding domain (Nef-ER fusion protein) to enable chemical control of Nef dimerization with 4-hydroxytamoxifen (4-HT) in cells (99). When Nef-ER and Hck were expressed together in rodent fibroblasts as a model system, 4-HT treatment induced Nef-ER dimer formation, Hck activation, and oncogenic transformation. Fibroblasts expressing Nef-ER and Hck in the presence of 4-HT produced a markedly enhanced transforming response relative to cells co-expressing WT Nef and Hck, indicating that enforced oligomerization may augment Hck activation by Nef. In complementary experiments, a Nef mutant defective for Hck SH3 domain binding (PxxPxxR to AxxAxxR mutant) suppressed signaling from the WT Nef-Hck complex, suggestive of a dominant-negative effect. Considering the Nef SH3-SH2 complex structures discussed above, the NefAxxAxxR mutant may form a mixed homodimer in cells (i.e. NefPxxPxxR NefAxxAxxR) to which only one Hck molecule can bind, producing an inactive, dead-end complex. These studies...
provided the first clue that Hck SH3 domain displacement from the SH2-kinase linker may not be sufficient to fully activate the kinase. Rather, juxtaposition of two Hck molecules may be required, such that autophosphorylation can proceed via a trans mechanism.

Mutants of HIV-1 Nef that are defective for homodimer formation have been reanalyzed in recent work (90). These mutants involve three hydrophobic residues that contribute to the Nef dimer interface in the crystal complexes with both the SH3 domain alone and with the dual SH3-SH2 domain of Hck (Nef Leu-112, Tyr-115, and Phe-121; Figs. 5 and 6). Recombinant full-length Nef proteins with these mutations are predominantly (Y115D) or exclusively (L112D and F121A) monomers by analytical size exclusion chromatography and show reduced propensity to form homodimers in the cell-based BiFC assay (90). The observation that these mutations do not completely abolish Nef homodimer formation in the BiFC assay likely relates to enhanced local concentrations of Nef at the cell membrane plus the fact that the YFP fluorophore is irreversibly reconstituted once formed (87). Nevertheless, each of these mutants showed greatly diminished capacity to activate the Tec-family kinases Itk and Btk at the cell membrane (90). Similar results were shown with Hck using the same cell-based assay (100), suggesting that activation of both kinase families requires a Nef dimer. Remarkably, one of these mutants, Nef-F121A, suppressed both Itk and Btk autophosphorylation below background levels observed in the absence of Nef while retaining interaction with each kinase (90), suggesting the formation of nonproductive Nef-kinase complexes. This observation provides further support for the trans-autophosphorylation mechanism of kinase activation modeled for Itk in Fig. 4A.

Crystal structures of Nef in complexes with isolated SH3 domains versus the Hck SH3-SH2 domain provide snapshots of very different homodimerization interfaces. This raises the important question of whether distinct dimer conformations are possible in solution and ultimately in cells. Moroco et al. (97) explored this issue using HX MS to compare the solution conformation of Nef alone and in complexes with the Hck SH3 and dual SH3-SH2 domain proteins previously used for crystallography. HX MS showed that the Nef αβ-helix is protected from deuterium uptake in Nef complexes with both SH3 and SH3-SH2 but not when bound to SH3 alone, consistent with a role for the Nef αβ helix in dimer formation. This result also shows that complex formation with Hck or other Src-family kinases stabilizes the Nef homodimer in solution. Subsequent comparative HX MS analysis of a Nef-D123N mutant showed protection of the αβ helix when bound to SH3-SH2 but not when bound to SH3 alone. This result is consistent with the crystal structures,
where Asp-123 contributes to Nef dimer formation when bound to SH3 alone but is surface-exposed when bound to SH3-SH2 (Fig. 7). These results support the idea that alternative dimeric states of Nef exist in solution and by extension in cells, despite a common fold of the structured core. Furthermore, Src-family kinase binding to Nef not only induces kinase activation but also triggers dynamic changes in Nef essential for recruitment of other host cell effectors.

Harnessing kinase activation by Nef for anti-retroviral drug discovery

Nef is a challenging target for traditional drug discovery campaigns based on high-throughput chemical library screening because it lacks intrinsic enzymatic or biochemical activity (101). Instead, Nef functions via interactions with diverse host cell proteins to enhance HIV-1 infectivity, replication, and immune escape as described above. Structural studies have established that host effector protein binding involves distinct Nef surfaces, complicating rational design of a universal Nef inhibitor capable of blocking its pleiotropic actions (33, 45, 67, 69). These issues have been circumvented in part through the development of a high-throughput screening assay for inhibitors of Nef-dependent activation of Hck (102, 103). In this approach, the recombinant Nef Hck complex was used for the primary chemical library screen with Hck serving as a “reporter” for Nef using a kinase assay designed for high-throughput screening. Subsequent counterscreens of the hit compounds against Hck alone allowed for identification of Nef-dependent inhibitors, which were subsequently shown to exhibit antiretroviral activity.

Two classes of small molecule inhibitors were identified through this screening strategy. The first class, characterized by a 4-amino-diphenylfurano-pyrimidine (DFP) scaffold, was discovered in a small library of kinase inhibitor–biased compounds (Fig. 8) (103). Whereas these compounds work directly via the Hck active site, they showed enhanced potency for Hck inhibition in the presence of Nef, suggesting that Nef binding may allosterically impact the Hck active site to enhance inhibitor binding. This conclusion is supported by subsequent HX MS studies of the Nef Hck complex in the presence of a DFP–based compound with antiretroviral activity (78). DFP–based Hck inhibitors also blocked Nef-mediated enhancement of viral replication across a wide range of Nef subtypes, providing additional evidence that Src-family kinase signaling is important to viral replication (52).

A subsequent screen of a large, diverse chemical library using this kinase-coupled approach identified a unique Nef inhibitor based on a hydroxypyrazole scaffold (102). This compound, a diphenyl hydroxypyrazolodiazene known as B9, bound directly to recombinant Nef by surface plasmon resonance (Fig. 8). B9 demonstrated inhibitory activity against multiple Nef functions,
including enhancement of viral infectivity, replication, and MHC-I down-regulation (102, 104). Synthesis and characterization of more than 200 analogs of B9 have been reported without the potentially carcinogenic diazene functionality (100, 105). Several of these analogs bound to recombinant Nef with \( K_D \) values in the nanomolar to picomolar range and inhibited Nef-mediated enhancement of HIV-1 replication in donor PBMCs with low nanomolar potency. Inhibitors in this class also blocked Nef-dependent activation of Itk and Hck, raising the possibility that they may influence Nef dimerization as a potential mechanism of action. Importantly, inhibitor treatment of cells expressing the kinases alone did not affect basal kinase activity, supporting a Nef-dependent mechanism of action. Ongoing challenges for Nef inhibitor development include structural analysis of their binding mode within Nef, which will clarify their mechanism of action and guide medicinal chemistry optimization for in vivo testing.

As described above, Nef prevents cell-surface display of MHC-I complexes with HIV-1 antigenic peptides on infected cells, allowing escape from cytotoxic T lymphocytes. In this way, Nef inhibits clearance of the virus and may contribute to establishment and maintenance of the persistent viral reservoir (106). Mujib et al. (104) showed that the direct acting Nef inhibitor B9, as well as several first-generation B9 analogs (105), restored MHC-I to the surface of HIV-infected CD4 T cells. Moreover, when Nef inhibitor–treated cells were co-cultured with autologous CD8 T cells expanded in the presence of HIV-1 antigenic peptides, the CD8 T cells became activated and killed the infected CD4 target cells. These findings raise the exciting possibility that Nef inhibitors may enhance CTL-mediated responses to help clear latent viral reservoirs. Newer analogs of B9 with enhanced affinity for Nef also retain the ability to reverse Nef-dependent down-regulation of MHC-I (100).

**Summary and prospects**

The Nef proteins of HIV-1 and other primate lentiviruses have been the subject of intense research for more than 30 years. Nef interacts with a diverse array of host cell proteins to benefit the virus, only a small subset of which are discussed here. This review focused primarily on structural aspects of Nef-dependent protein-tyrosine kinase activation and the relationship of these interactions to the viral life cycle, intracellular trafficking pathways, and immune escape.

Recurrent themes in the biology of Nef relate to its dynamic nature, diverse signaling partners, and ability to form alternative homodimer conformations and possibly larger oligomeric complexes. These versatile properties allow Nef to assemble signaling complexes that bypass normal cellular control mechanisms. This concept is particularly clear for Nef-mediated activation of nonreceptor tyrosine kinases, which overrides normal kinase control mechanisms through recruitment and juxtaposition of kinase molecules in the membrane. In this way, Nef mimics well-known mechanisms of cytoplasmic kinase activation by receptor tyrosine kinases as well as antigen and cytokine receptors. Interestingly, mutants of Nef attenuated for homodimer formation not only fail to activate Src- and Tec-family kinases, but are also unable to down-regulate CD4 and MHC-I. Yet in crystal structures of Nef in complex with AP-1/MHC-I (PDB code 4EN2) as well as AP-2/CD4 (PDB code 6URI), Nef is present as a monomer. This observation suggests that dynamic monomer-dimer transitions may be important for some but not all Nef functions. In the case of MHC-I down-regulation, Nef-dependent Src-family kinase activation has been linked to this event. In addition, interaction with the Hck regulatory region induces a Nef conformation compatible with AP-1/MHC-I recruitment (Fig. 7), suggesting that Src-family kinase engagement may induce a dimer-monomer transition in the MHC-I down-regulation pathway. On the other hand, a recent structure of Nef in complex with AP-2 and the cytoplasmic tail of CD4 shows that residues involved in homodimer formation in complexes with Src kinases interact either directly with CD4 or internally with Nef (33). In the case of CD4, therefore, mutations that render Nef defective for homodimer formation may also prevent interaction with AP-2 and CD4 directly. Regardless of the mechanism, mutagenesis studies show that homodimerization is linked to most Nef functions, and pharmacological perturbation of Nef dimer formation may provide a new approach to antiretroviral therapy with the potential for viral clearance.

---

**Funding and additional information**—Work in the authors’ laboratories has been supported by National Institutes of Health Grants AI057083, AI102724, and AI126617 (to T. E. S.) and GM086507, GM101135, and CA233978 (to J. R. E.). The content is solely the
JBC REVIEWS: Modulation of host cell tyrosine kinases by HIV-1 Nef

responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: NRTI, nucleoside reverse transcriptase inhibitor; cART, combination antiretroviral therapy; LRA, latency reversal agent; SIV, simian immunodeficiency virus; MHC, major histocompatibility complex; TGN, trans-Golgi network; PPII, polyproline type II; SH2, Src homology 2; SH3, Src homology 3; HX, hydrogen-deuterium exchange; BiFC, bimolecular fluorescence complementation; PBMC, peripheral blood mononuclear cell; ER, endoplasmic reticulum; 4-HT, 4-hydroxytamoxifen; DFP, 4-amino-diphenylfurano-pyrimidine; PDB, Protein Data Bank; YFP, yellow fluorescent protein.

References

1. Jaffe, H. W. (2008) The early days of the HIV-AIDS epidemic in the U.S. A. Nat. Immunol. 9, 1201–1203 CrossRef Medline

2. Marwick, C. (1987) AZT (zidovudine) just a step away from FDA approval for AIDS therapy. JAMA 257, 1281–1282 CrossRef Medline

3. Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Hauberich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., Hirsch, M. S., and Merigan, T. C. (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N. Engl. J. Med. 335, 1081–1090 CrossRef Medline

4. Vella, S., Schwartlander, B., Sow, S. P., Eholie, S. P., and Murphy, R. L. (2012) The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS 26, 1231–1241 CrossRef Medline

5. Sepkowitz, K. A. (2001) AIDS—the first 20 years. N. Engl. J. Med. 344, 1764–1772 CrossRef Medline

6. Dionne, B. (2019) Key principles of antiretroviral pharmacology. Infect. Dis. Clin. North Am. 33, 787–805 CrossRef Medline

7. Rerkson, S., Patitsoulis, P., Niyasatthiya, C., Kaewkungwal, J., Chiu, J., Paris, R., Premji, N., Namwat, C., de Souza, M., Adams, E., Benson, M., Gurunathan, S., Tartaglia, J., McNeil, J. G., Francis, D. P., Hadley, W. H., Ferrari, J., and Phair, J. P. (2020) Vaccination with ALVAC/AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 383, 2209–2220 CrossRef Medline

8. Kim, Y., Anderson, J. L., and Lewin, S. R. (2018) Getting the “kill” into “shock and kill”: strategies to eliminate latent HIV. Cell Host Microbe 23, 14–26 CrossRef Medline

9. McBriern, J. B., Mavignier, M., Franchitti, L., Smith, S. A., White, E., Spagnuolo, R. A., Irlbeck, D. M., Mattingly, C., Ho, P. T., Schoof, N., Cammon, J. G., Francis, D. P., Hadley, W. H., Ferrari, J., and Phair, J. P. (2020) Neutrophil CD11b expression is associated with peripheral blood mononuclear cell depletion in the setting of non-AIDS wasting: results from a randomized, double-blind, placebo-controlled trial of a novel antiretroviral agent. J. Virol. 94, e01322–01322 CrossRef Medline

10. Pham, T. N., Lukhele, S., Hajjar, F., Routy, J. P., and Cohen, E. A. (2014) HIV Nef proteins hijack membrane traffic to promote infection. J. Virol. 93, e01322–01322 CrossRef Medline

11. Pereira, E. A., and daSilva, L. L. (2016) HIV-1 Nef: taking control of protein trafficking. Traffic 17, 976–996 CrossRef Medline

12. Mariani, R., and Skowronski, J. (1993) CD4 down-regulation by nef alleles isolated from human immunodeficiency virus type 1-infected individuals. Proc. Natl. Acad. Sci. U. S. A. 90, 5549–5553 CrossRef Medline

13. Lima, J. (2003) The physiological relevance of CD4 receptor down-modulation during HIV infection. Curr. HIV Res. 1, 167–184 CrossRef Medline

14. Pham, T. N., Lukhele, S., Hajjar, F., Routy, J. P., and Cohen, E. A. (2014) HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology 11, 15 CrossRef Medline

15. Pitcher, C., Höning, S., Fingerhut, A., Bowers, K., and Marsh, M. (1999) Cluster of differentiation antigen 4 (CD4) endocytosis and adaptor complex binding require activation of the CD4 endocytosis signal by serine phosphorylation. Mol. Biol. Cell 10, 677–691 CrossRef Medline

16. Chaudhuri, R., Lindwasser, O. W., Smith, W. J., Hurley, J. H., and Bonifacino, J. S. (2007) Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction.
of Nef with the AP2 clathrin adaptor. *J. Virol.* **81**, 3877–3890 CrossRef Medline

32. Garcia, J. V., and Miller, A. D. (1991) Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. *Nature* **350**, 508–511 CrossRef Medline

33. Kwon, Y., Kaake, R. M., Echeverria, I., Suarez, M., Karimian Shamsabadi, E. A., and Pizzato, M. (2015) HIV-1 Nef promotes infection by excluding SERINC from virion incorporation. *J. Virol.* **89**, 2906–2914 CrossRef Medline

34. Binette, J., Dubé, M., Mercier, J., Halawani, D., Latterich, M., and Cohen, K. (2007) Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. *Retrovirology* **4**, 75 CrossRef Medline

35. Chowers, M. Y., Spina, C. A., Kwoh, T. J., Fitch, N. J., Richman, D. D., and Guatelli, J. C. (1994) Optimal infectivity in *in vitro* of human immunodeficiency virus type 1 requires an intact nef gene. *J. Virol.* **68**, 2906–2914 CrossRef Medline

36. Münch, J., Rajan, D., Schindler, M., Specht, A., Rücker, E., Novembre, F. J., Nerrrient, E., Müller-Truttin, M. C., Peeters, M., Hahn, B. H., and Kirchhoff, F. (2007) Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. *J. Virol.* **81**, 13852–13864 CrossRef Medline

37. Basmaciogullari, S., and Pizzato, M. (2014) The activity of Nef on HIV-1 infectivity. *Front. Microbiol.* **5**, 232 CrossRef Medline

38. Rosa, A., Chande, A., Ziglio, S., De Sanctis, V., Bertorelli, R., Goh, S. L., McCaulay, S. M., Nowosieleka, A., Antonarakis, S. E., Luban, J., Santoni, S., F. A., and Pizzato, M. (2015) HIV-1 Nef promotes infection by excluding SERINC from virion incorporation. *Nature* **526**, 212–217 CrossRef Medline

39. Usami, Y., Wu, Y., and Göttlinger, H. G. (2015) SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. *Nature* **526**, 218–223 CrossRef Medline

40. Sood, C., Marin, M., Chande, A., Pizzato, M., and Melikyan, G. B. (2017) SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins. *J. Biol. Chem.* **292**, 6014–6026 CrossRef Medline

41. Shi, J., Xiong, R., Zhou, T., Su, P., Zhang, X., Qiu, X., Li, H., Li, S., Yu, C., Wang, B., Ding, C., Smithgall, T. E., and Zheng, Y. H. (2018) HIV-1 Nef antagonizes SERINC5 restriction by downregulation of SERINC5 via the endosome/lysosome system. *J. Virol.* **92**, e00196 CrossRef Medline

42. Dikeakos, I. D., Atkins, K. M., Thomas, L., Emerit-Sedlak, L., Byeon, I. J., Jung, A., Ahn, J., Wortman, M. D., Kukul, B., Saito, M., Koizumi, H., Williamon, D. M., Hiyoshi, M., Barklis, E., Takiguchi, M., et al. (2010) Small molecule inhibition of HIV-1-induced MHC-I down-regulation identifies a temporarily regulated switch in Nef function. *Mol. Biol. Cell* **21**, 3279–3292 CrossRef Medline

43. Hung, C. H., Thomas, L., Ruby, C. E., Atkins, K. M., Morris, N. P., Knight, Z. A., Scholz, I., Barklis, E., Weinberg, A. D., Shokat, K. M., and Thomas, G. (2007) HIV-1 Nef assembles a Src family kinase-ZAP-70/Syk-PI3K signaling complex to downregulate cell-surface MHC-I. *Cell Host Microbe* **1**, 121–133 CrossRef Medline

44. Kasper, M. R., Roeth, J. F., Williams, M., Filzen, T. M., Fleis, R. I., and Collins, K. L. (2005) HIV-1 Nef disrupts antigen presentation early in the secretory pathway. *J. Biol. Chem.* **280**, 12840–12848 CrossRef Medline

45. Jia, X., Singh, R., Homann, S., Yang, H., Guatelli, J., and Xiong, Y. (2012) Structural basis of evasion of cellular adaptive immunity by HIV-1 Nef. *Nat. Struct. Mol. Biol.* **19**, 701–706 CrossRef Medline

46. Pawlak, E. N., and Dikeakos, I. D. (2015) HIV-1 Nef: a master manipulator of the membrane trafficking machinery mediating immune evasion. *Biochim. Biophys. Acta* **1850**, 733–741 CrossRef Medline

47. Saksela, K., Cheng, G., and Baltimore, D. (1995) Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. *EMBO J.* **14**, 484–491 CrossRef

48. Lee, C.-H., LeFevre-Bernt, M., Schifer, F., Huse, M., Lee, C.-H., Kuriyan, J., and Miller, W. T. (1997) Activation of the Src-family protein kinase Hck by SH3 domain displacement. *Nature* **385**, 650–653 CrossRef Medline

49. Briggs, S. D., Sharkey, M., Stevenson, M., and Smithgall, T. E. (1997) SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1. *J. Biol. Chem.* **272**, 17899–17902 CrossRef Medline

50. Lerner, E. C., and Smithgall, T. E. (2000) SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in *vivo*. *Nat. Struct. Biol.* **9**, 365–369 CrossRef Medline

51. Narute, P. S., and Smithgall, T. E. (2012) Nef alleles from all major HIV-1 clades activate Src-family kinases and enhance HIV-1 replication in an inhibitor-sensitive manner. *PLoS One* **7**, e32561 CrossRef Medline

52. Komuro, I., Yokota, Y., Yasuda, S., Iwamoto, A., and Kagawa, K. S. (2003) CSF-induced and HIV-1-mediated distinct regulation of Hck and C/EBPβ represent a heterogeneous susceptibility of monocye-derived macrophages to M-tropic HIV-1 infection. *J. Exp. Med.* **198**, 443–453 CrossRef Medline

53. Biggs, T. E., Cooke, S. J., Barton, C. H., Harris, M. P., Saksela, K., and Mann, D. A. (1999) Induction of activator protein 1 (AP-1) in macrophages by human immunodeficiency virus type-1 Nef is a cell-type-specific response that requires both hck and MAPK signaling events. *J. Mol. Biol.* **290**, 21–35 CrossRef Medline

54. Collette, Y., Dutartre, H., Benziane, A., Ramos-Morales, F., Benarous, R., Harris, M., and Olive, D. (1996) Physical and functional interaction of Nef with Lck–HIV-1 Nef-induced T-cell signaling defects. *J. Biol. Chem.* **271**, 6333–6341 CrossRef Medline

55. Briggs, S. D., Echeverria, I., Wang, J. K., Chen, Y. L., and Trono, D. (2006) HIV-1 Nef selectively activates the Src family kinase Hck during infection of human T cells. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 1992–1997 CrossRef Medline

56. Hernandez, R. G., and Saksela, K. (2000) Interactions of HIV-1 Nef with cellular signal transducing proteins. *Front. Biosci.* **5**, D268–D283 CrossRef Medline

57. Mangasarian, A., Piguet, V., Wang, J. K., Chen, Y. L., and Trono, D. (1999) Nef-induced CD4 and major histocompatibility class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal α helix and proline repeat of Nef selectively regulate MHC-I trafficking. *J. Virol.* **73**, 1964–1973 CrossRef Medline

58. Zhang, W., Wang, Y., Gallo, R. C., and Lucas, L. (1987) The functional characterization of the Herpesvirus saimiri Tip-C484 protein. *J. Biol. Chem.* **262**, 1282–1292 CrossRef Medline

59. Trible, R. P., Emerit-Sedlak, L., and Smithgall, T. E. (2006) HIV-1 Nef selectively activates SRC family kinases HCK, LYN, and c-SRC through direct SH3 domain interaction. *J. Biol. Chem.* **281**, 27029–27038 CrossRef Medline

60. Herna, R. G., and Saksela, K. (2000) Interactions of HIV-1 Nef with cellular signal transducing proteins. *Front. Biosci.* **5**, D268–D283 CrossRef Medline

61. Trible, R. P., Emerit-Sedlak, L., Mitaku, M., and Smithgall, T. E. (2006) HIV-1 Nef selectively activates SRC family kinases HCK, LYN, and c-SRC through direct SH3 domain interaction. *J. Biol. Chem.* **281**, 27029–27038 CrossRef Medline
structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase. Nat. Struct. Biol. 3, 340–345 CrossRef Medline
67. Alvarado, J. J., Tarafdar, S., Yeh, J. L., and Smithgall, T. E. (2014) Interaction with the Src homology (SH3-SH2) region of the Src-family kinase Hck structures the HIV-1 Nef dimer for kinase activation and effector recruitment. J. Biol. Chem. 289, 28539–28553 CrossRef Medline
68. Sichere, F., Moree, L., and Kuriyan, J. (1997) Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602–609 CrossRef Medline
69. Ren, X., Park, S. Y., Bonifacino, J. S., and Hurley, J. H. (2014) How HIV-1 Nef hijacks the AP-2 clathrin adaptor to downregulate CD4. Elife 3, e01754 CrossRef Medline
70. Choi, H. J., and Smithgall, T. E. (2004) Conserved residues in the HIV-1 Readinger, J. A., Schiralli, G. M., Jiang, J. K., Thomas, C. J., August, A., Henderson, A. J., and Schwartzberg, P. L. (2008) Selective targeting of ITK blocks multiple steps of HIV replication. Proc. Natl. Acad. Sci. U. S. A. 105, 6684–6689 CrossRef Medline
71. Hiipakka, M., Poikonen, K., and Saksela, K. (1999) SH3 domains with structural basis of a protein inhibitor against the HIV-1 pathogenicity factor Nef. PLoS One 6, e20333 CrossRef Medline
72. Breuer, S., Schievink, S. I., Schulte, A., Blankenfeldt, W., Fackler, O. T., and Geyer, M. (2011) Conformation of the dileucine-based sorting motif in HIV-1 Nef revealed by intermolecular domain assembly. Traffic 12, 867–877 CrossRef Medline
73. Breuer, S., Schievink, S. I., Schulte, A., Blankenfeldt, W., Fackler, O. T., and Geyer, M. (2011) Molecular design, functional characterization and structural basis of a protein inhibitor against the HIV-1 pathogenicity factor Nef. PLoS One 6, e20333 CrossRef Medline
74. Li, W. F., Aryal, M., Shu, S. T., and Smithgall, T. E. (2020) HIV-1 Nef dimers short-circuit immune receptor signaling by activating Tec-family kinases at the host cell membrane. J. Biol. Chem. 295, 5163–5174 CrossRef Medline
75. Pene-Dumitrescu, T., Shu, S. T., Wales, T. E., Alvarado, J. I., Shi, H., Nar-ute, P., Moroco, J. A., Yeh, J. I., Engen, I. R., and Smithgall, T. E. (2012) HIV-1 Nef interaction influences the ATP-binding site of the Src-family kinase. Hck. BMC Mol. Biol. 12, 1 CrossRef Medline
76. Englander, S. W., and Kallenbach, N. R. (1983) Hydrogen exchange and mass spectrometry: a new tool for protein structure elucida-	ion. Annu. Rev. Biophys. 16, 521–655 CrossRef Medline
77. Zhang, Z., and Smith, D. L. (1993) Determination of amide hydrogen exchange by mass spectrometry: a new tool for protein structure elucidation. Protein Sci. 2, 522–531 CrossRef Medline
78. Wales, T. E., Hochrein, J. M., Morgan, C. R., Emerit-Sedlak, L. A., Smithgall, T. E., and Engen, I. R. (2015) Subtle dynamic changes accompany Hck activation by HIV-1 Nef and are reversed by an antiretroviral kinase inhibitor. Biochemistry 54, 6382–6391 CrossRef Medline
79. Schindler, T., Sicheri, F., Pico, A., Gaitz, A., Levitzki, A., and Kuriyan, J. (1999) Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3, 639–648 CrossRef Medline
80. Briggs, S. D., and Smithgall, T. E. (1999) SH2-kinase linker mutations release Hck tyrosine kinase and transforming activities in rat-2 fibroblasts. J. Biol. Chem. 274, 26579–26583 CrossRef Medline
81. Dorman, H. R., Close, D., Wingert, B. M., Camacho, C. J., Johnston, P. A., and Smithgall, T. E. (2019) Discovery of non-peptide small molecule allosteric modulators of the Src-family kinase, Hck. Front. Chem. 7, 822 CrossRef Medline
82. Moroco, J. A., Craigio, J. K., Iacob, R. E., Wales, T. E., Engen, I. R., and Smithgall, T. E. (2014) Differential sensitivity of Src-family kinases to activation by SH3 domain displacement. PLoS One 9, e105629 CrossRef Medline
83. Andreotti, A. H., Schwartzberg, P. L., Joseph, R. E., and Berg, L. I. (2010) T-cell signaling regulated by the Tec family kinase, Itk. Cold Spring Harb. Perspect. Biol. 2, a002287 CrossRef Medline
84. Hussain, A., Yu, L., Faryal, R., Mohammad, D. K., Mohamed, A. J., and Smith, C. I. (2011) TEC family kinases in health and disease—loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK. FEBS J. 278, 2001–2010 CrossRef Medline
85. Readinger, J. A., Schiralli, G. M., Jiang, J. K., Thomas, C. J., August, A., Henderson, A. J., and Schwartzberg, P. L. (2008) Selective targeting of HIV-1 virulence factor, Nef. Drug Discov. Today Technol. 10, 523–529 CrossRef Medline
86. Emerit-Sedlak, L. A., Narute, P., Shu, S. T., Poe, J. A., Shi, H., Yanamala, N., Alvarado, J. J., Lazo, J. S., Yeh, J. I., Johnston, P. A., and Smithgall, T. E. (2013) Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity. Chem. Biol. 20, 82–91 CrossRef Medline
103. Emert-Sedlak, L., Kodama, T., Lerner, E. C., Dai, W., Foster, C., Day, B. W., Lazo, J. S., and Smithgall, T. E. (2009) Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem. Biol. 4, 939–947 CrossRef Medline

104. Mujib, S., Saiyed, A., Fadel, S., Bozorgzad, A., Aidarus, N., Yue, F. Y., Benko, E., Kovacs, C., Emert-Sedlak, L., Smithgall, T. E., and Ostrowski, M. A. (2017) Pharmacologic HIV-1 Nef blockade enhances the recognition and elimination of latently HIV-1 infected CD4 T cells by autologous CD8 T cells. J. Clin. Invest. Insight 2, e93684 CrossRef Medline

105. Emert-Sedlak, L. A., Loughran, H. M., Shi, H., Kulp, J. L., 3rd, Shu, S. T., Zhao, J., Day, B. W., Wrobel, J. E., Reitz, A. B., and Smithgall, T. E. (2016) Synthesis and evaluation of orally active small molecule HIV-1 Nef antagonists. Bioorg. Med. Chem. Lett. 26, 1480–1484 CrossRef Medline

106. Omondi, F. H., Chandrarathna, S., Mujib, S., Brumme, C. J., Jin, S. W., Sudderuddin, H., Miller, R. L., Rahimi, A., Laeyendecker, O., Bonner, P., Yue, F. Y., Benko, E., Kovacs, C. M., Brockman, M. A., Ostrowski, M., et al. (2019) HIV subtype and Nef-mediated immune evasion function correlate with viral reservoir size in early-treated individuals. J. Virol. 93, e01832 CrossRef Medline